High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

Abstract Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended in international guidelines. In thes...

Full description

Bibliographic Details

Main Authors:	Hanne Madsen, Charlotte G. Mortz, Carsten Bindslev‐Jensen, Mette Reilev, Jesper Hallas, Daniel P. Henriksen
Format:	Artigo
Language:	Inglês
Published:	Wiley 2021-12-01
Series:	Clinical and Translational Allergy
Subjects:	Adhärence antihistaminika nicht sedierend chronische urtikaria omalizumab richtlinie
Online Access:	https://doi.org/10.1002/clt2.12085
Tags:	Add Tag No Tags, Be the first to tag this record!